Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys

Ge Liu, Langzhou Song, David Beasley, Robert Putnak, Jason Parent, John Misczak, Hong Li, Lucia Reiserova, Xiangyu Liu, Haijun Tian, Wenzhe Liu, Darlene Labonte, Lihua Duan, Youngsun Kim, Linda Travalent, Devin Wigington, Bruce Weaver, Lynda Tussey

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The envelope (E) protein of flaviviruses includes three domains, EI, EII, and EIII, and is the major protective antigen. Because EIII is rich in type-specific and subcomplex-specific neutralizing epitopes and is easy to express, it is particularly attractive as a recombinant vaccine antigen. VaxInnate has developed a vaccine platform that genetically links vaccine antigens to bacterial flagellin, a Toll-like receptor 5 ligand. Here we report that tetravalent dengue vaccines (TDVs) consisting of four constructs, each containing two copies of EIII fused to flagellin (R3.2x format), elicited robust and long-lived neutralizing antibodies (geometric mean titers of 200 to 3,000), as measured with a 50% focus reduction neutralization test (FRNT<inf>50</inf>). In an immunogenicity study, rhesus macaques (n = 2) immunized subcutaneously with 10 μgor90 μg of TDV three or four times, at 4- to 6-week intervals, developed neutralizing antibodies to four dengue virus (DENV) serotypes (mean post-dose 3 FRNT<inf>50</inf> titers of 102 to 601). In an efficacy study, rhesus macaques (n = 4) were immunized intramuscularly with 16 μgor48 μg of TDV or a placebo control three times, at 1-month intervals. The animals that received 48-doses of TDV developed neutralizing antibodies against the four serotypes (geometric mean titers of 49 to 258) and exhibited reduced viremia after DENV-2 challenge, with a group mean viremia duration of 1.25 days and 2 of 4 animals being completely protected, compared to the placebo-treated animals, which all developed viremia, with a mean duration of 4 days. In conclusion, flagellin-EIII fusion vaccines are immunogenic and partially protective in a nonhuman primate model.

Original languageEnglish (US)
Pages (from-to)516-525
Number of pages10
JournalClinical and Vaccine Immunology
Volume22
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Dengue Vaccines
Flagellin
Haplorhini
Viremia
Fusion reactions
Neutralizing Antibodies
Dengue Virus
Animals
Vaccines
Macaca mulatta
Viruses
Antigens
Toll-Like Receptor 5
Placebos
Bacterial Antigens
Neutralization Tests
Synthetic Vaccines
Primates
Epitopes
Ligands

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys. / Liu, Ge; Song, Langzhou; Beasley, David; Putnak, Robert; Parent, Jason; Misczak, John; Li, Hong; Reiserova, Lucia; Liu, Xiangyu; Tian, Haijun; Liu, Wenzhe; Labonte, Darlene; Duan, Lihua; Kim, Youngsun; Travalent, Linda; Wigington, Devin; Weaver, Bruce; Tussey, Lynda.

In: Clinical and Vaccine Immunology, Vol. 22, No. 5, 01.05.2015, p. 516-525.

Research output: Contribution to journalArticle

Liu, G, Song, L, Beasley, D, Putnak, R, Parent, J, Misczak, J, Li, H, Reiserova, L, Liu, X, Tian, H, Liu, W, Labonte, D, Duan, L, Kim, Y, Travalent, L, Wigington, D, Weaver, B & Tussey, L 2015, 'Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys', Clinical and Vaccine Immunology, vol. 22, no. 5, pp. 516-525. https://doi.org/10.1128/CVI.00770-14
Liu, Ge ; Song, Langzhou ; Beasley, David ; Putnak, Robert ; Parent, Jason ; Misczak, John ; Li, Hong ; Reiserova, Lucia ; Liu, Xiangyu ; Tian, Haijun ; Liu, Wenzhe ; Labonte, Darlene ; Duan, Lihua ; Kim, Youngsun ; Travalent, Linda ; Wigington, Devin ; Weaver, Bruce ; Tussey, Lynda. / Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys. In: Clinical and Vaccine Immunology. 2015 ; Vol. 22, No. 5. pp. 516-525.
@article{6f531f1f40314aac99ab909f4c70d0d2,
title = "Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys",
abstract = "The envelope (E) protein of flaviviruses includes three domains, EI, EII, and EIII, and is the major protective antigen. Because EIII is rich in type-specific and subcomplex-specific neutralizing epitopes and is easy to express, it is particularly attractive as a recombinant vaccine antigen. VaxInnate has developed a vaccine platform that genetically links vaccine antigens to bacterial flagellin, a Toll-like receptor 5 ligand. Here we report that tetravalent dengue vaccines (TDVs) consisting of four constructs, each containing two copies of EIII fused to flagellin (R3.2x format), elicited robust and long-lived neutralizing antibodies (geometric mean titers of 200 to 3,000), as measured with a 50{\%} focus reduction neutralization test (FRNT50). In an immunogenicity study, rhesus macaques (n = 2) immunized subcutaneously with 10 μgor90 μg of TDV three or four times, at 4- to 6-week intervals, developed neutralizing antibodies to four dengue virus (DENV) serotypes (mean post-dose 3 FRNT50 titers of 102 to 601). In an efficacy study, rhesus macaques (n = 4) were immunized intramuscularly with 16 μgor48 μg of TDV or a placebo control three times, at 1-month intervals. The animals that received 48-doses of TDV developed neutralizing antibodies against the four serotypes (geometric mean titers of 49 to 258) and exhibited reduced viremia after DENV-2 challenge, with a group mean viremia duration of 1.25 days and 2 of 4 animals being completely protected, compared to the placebo-treated animals, which all developed viremia, with a mean duration of 4 days. In conclusion, flagellin-EIII fusion vaccines are immunogenic and partially protective in a nonhuman primate model.",
author = "Ge Liu and Langzhou Song and David Beasley and Robert Putnak and Jason Parent and John Misczak and Hong Li and Lucia Reiserova and Xiangyu Liu and Haijun Tian and Wenzhe Liu and Darlene Labonte and Lihua Duan and Youngsun Kim and Linda Travalent and Devin Wigington and Bruce Weaver and Lynda Tussey",
year = "2015",
month = "5",
day = "1",
doi = "10.1128/CVI.00770-14",
language = "English (US)",
volume = "22",
pages = "516--525",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys

AU - Liu, Ge

AU - Song, Langzhou

AU - Beasley, David

AU - Putnak, Robert

AU - Parent, Jason

AU - Misczak, John

AU - Li, Hong

AU - Reiserova, Lucia

AU - Liu, Xiangyu

AU - Tian, Haijun

AU - Liu, Wenzhe

AU - Labonte, Darlene

AU - Duan, Lihua

AU - Kim, Youngsun

AU - Travalent, Linda

AU - Wigington, Devin

AU - Weaver, Bruce

AU - Tussey, Lynda

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The envelope (E) protein of flaviviruses includes three domains, EI, EII, and EIII, and is the major protective antigen. Because EIII is rich in type-specific and subcomplex-specific neutralizing epitopes and is easy to express, it is particularly attractive as a recombinant vaccine antigen. VaxInnate has developed a vaccine platform that genetically links vaccine antigens to bacterial flagellin, a Toll-like receptor 5 ligand. Here we report that tetravalent dengue vaccines (TDVs) consisting of four constructs, each containing two copies of EIII fused to flagellin (R3.2x format), elicited robust and long-lived neutralizing antibodies (geometric mean titers of 200 to 3,000), as measured with a 50% focus reduction neutralization test (FRNT50). In an immunogenicity study, rhesus macaques (n = 2) immunized subcutaneously with 10 μgor90 μg of TDV three or four times, at 4- to 6-week intervals, developed neutralizing antibodies to four dengue virus (DENV) serotypes (mean post-dose 3 FRNT50 titers of 102 to 601). In an efficacy study, rhesus macaques (n = 4) were immunized intramuscularly with 16 μgor48 μg of TDV or a placebo control three times, at 1-month intervals. The animals that received 48-doses of TDV developed neutralizing antibodies against the four serotypes (geometric mean titers of 49 to 258) and exhibited reduced viremia after DENV-2 challenge, with a group mean viremia duration of 1.25 days and 2 of 4 animals being completely protected, compared to the placebo-treated animals, which all developed viremia, with a mean duration of 4 days. In conclusion, flagellin-EIII fusion vaccines are immunogenic and partially protective in a nonhuman primate model.

AB - The envelope (E) protein of flaviviruses includes three domains, EI, EII, and EIII, and is the major protective antigen. Because EIII is rich in type-specific and subcomplex-specific neutralizing epitopes and is easy to express, it is particularly attractive as a recombinant vaccine antigen. VaxInnate has developed a vaccine platform that genetically links vaccine antigens to bacterial flagellin, a Toll-like receptor 5 ligand. Here we report that tetravalent dengue vaccines (TDVs) consisting of four constructs, each containing two copies of EIII fused to flagellin (R3.2x format), elicited robust and long-lived neutralizing antibodies (geometric mean titers of 200 to 3,000), as measured with a 50% focus reduction neutralization test (FRNT50). In an immunogenicity study, rhesus macaques (n = 2) immunized subcutaneously with 10 μgor90 μg of TDV three or four times, at 4- to 6-week intervals, developed neutralizing antibodies to four dengue virus (DENV) serotypes (mean post-dose 3 FRNT50 titers of 102 to 601). In an efficacy study, rhesus macaques (n = 4) were immunized intramuscularly with 16 μgor48 μg of TDV or a placebo control three times, at 1-month intervals. The animals that received 48-doses of TDV developed neutralizing antibodies against the four serotypes (geometric mean titers of 49 to 258) and exhibited reduced viremia after DENV-2 challenge, with a group mean viremia duration of 1.25 days and 2 of 4 animals being completely protected, compared to the placebo-treated animals, which all developed viremia, with a mean duration of 4 days. In conclusion, flagellin-EIII fusion vaccines are immunogenic and partially protective in a nonhuman primate model.

UR - http://www.scopus.com/inward/record.url?scp=84929092600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929092600&partnerID=8YFLogxK

U2 - 10.1128/CVI.00770-14

DO - 10.1128/CVI.00770-14

M3 - Article

C2 - 25761459

AN - SCOPUS:84929092600

VL - 22

SP - 516

EP - 525

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 5

ER -